Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
← catalyst calendarNCT07348640 · readout in 499 d
Sponsored by Guerbet (industry) · GBT.PA — their whole pipeline →. With Bracco Imaging S.p.A..
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Diagnostic
Enrollment
315estimated
Sites
41
Countries
Canada, Czechia, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-28 | estimated | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Steno-occlusive Disease
Interventions
- Drug: gadopiclenol
- Drug: Gadoterate meglumine (Dotarem)
Primary outcome
what the primary-completion date above is the date OFNon-inferiority
measured 30 days
Permalink · GBT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed